Relative to NKTR-214 alone, NKTR-214 and anti-PD-1 combination resulted in somewhat lower levels of CD8+ T cells in the blood, which could be due to enhanced transitioning of CD8+ T cells from the blood into the tumor mass as observed in this combination treatment group (Supplementary Fig. 1d). The gene discussed is CD8A; the disease is neoplasm.